Long-Term Clinical Outcomes Of Subjects Enrolled In The RxSight Light Adjustable Lens (LAL) And Light Delivery Device (LDD) New Enrollment Study

Conditions

• Aphakia Cataract

Eligibility Criteria

Sex

ALL

Age

N/A - N/A

Healthy Volunteers

Not accepted

Interventions

• Light Adjustable lens (LAL) and Light Delivery Device (LDD) — DEVICE
  Experimental treatment group received Light adjustable lens with Light delivery Device treatments

Study Details

This is an observational, follow up study of subjects previously enrolled in the "RxSight Light Adjustable Lens (LAL) and Light Delivery Device (LDD) New Enrollment Study". The primary objective of this study is to collect long-term safety and effectiveness data on RxSight LAL in subjects previously implanted in the "RxSight Light Adjustable Lens (LAL) and Light Delivery Device (LDD) New Enrollment Study".

Key Dates

First listed

Jan 16, 2026

Start date

Nov 13, 2025

Status verified

Aug 2026

Primary completion

Sep 30, 2026

Completion

Dec 31, 2026

Study Design

Enrollment

108 participants (estimated)

Arms

• Arm: Light adjustable lens (LAL) and Light Delivery Device (LDD)
  Light adjustable lens (LAL) and Light Delivery Device (LDD)

Primary Outcome Measure

Mean absolute manifest refraction spherical equivalent (|MRSE|) at the Long-Term follow up visit [ Time Frame: Up to 55 months ]

Locations (1)

Find similar trials in San Antonio, TX